8 Biotechnology Stocks to Buy Now

8 Biotechnology Stocks to Buy Now

This week, 8 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, XBiotech, Inc.’s (XBIT) ratings are up from a C last week to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of XBIT stock.

This is a strong week for Lion Biotechnologies, Inc. (LBIO). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of LBIO stock.

MediciNova, Inc. (MNOV) gets a higher grade this week, advancing from a B last week to a A. MediciNova, Inc. acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

The rating of Stellar Biotechnologies, Inc. (SBOT) moves up this week, rising from a D to a B. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of SBOT stock.

Opexa Therapeutics, Inc.’s (OPXA) ratings are looking better this week, moving up to a B from last week’s C. Opexa Therapeutics, Inc. develops cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, pancreatic, and cardiac conditions. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of OPXA stock.

Organovo Holdings, Inc. (ONVO) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ONVO stock.

GlobeImmune, Inc. (GBIM) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of GBIM stock.

ArQule, Inc. (ARQL) is seeing ratings go up from a C last week to a B this week. ArQule, Inc. is a biotechnology company that is engaged in the research and development of cancer therapeutics. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ARQL stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/07/8-biotechnology-stocks-to-buy-now-5/.

©2019 InvestorPlace Media, LLC